Phase 1b Dose Escalation followed by Phase 2 treatment. Participants will be evaluable for inclusion in the Phase 1b and Phase 2 portions of the study if they receive at least one dose of protocol therapy.

Conditions

Leukemia, other

Phase III

What is the purpose of this trial?

The main purpose of this study is to determine the safe and recommended dose of APR-246 in combination with azacitidine as well as to see if this combination of therapy improves overall survival.

  • Trial with
    Aprea Therapeutics AB
  • Start Date
    06/19/2019
  • End Date
    05/30/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image
  • Last Updated
    08/07/2019
  • Study HIC
    #2000024507